Pathological and functional significance of Semaphorin-5A in pancreatic cancer progression and metastasis

Sugandha Saxena, Yuri Hayashi, Lingyun Wu, Mohammad Awaji, Pranita Atri, Michelle L. Varney, Abhilasha Purohit, Satyanarayana Rachagani, Surinder Kumar Batra, Rakesh K Singh

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Semaphorin-5A (SEMA5A) has differential cell surface expression between normal and cancer cells and represents an attractive target for therapeutic intervention in pancreatic cancer (PC). In this study, we delineated the pathological expression and significance of SEMA5A during PC progression and metastasis. We utilized human tissue microarrays and different PC mouse models (Pdx1-cre; LSL- Kras(G12D), Pdx1- Cre; LSL-Kras(G12D); LSL-p53(R172H) and RIP1-Tag2) to analyze SEMA5A expression during PC progression. Using human patients and different mouse models, we demonstrated that SEMA5A expression was highest in liver metastases, followed by primary pancreatic tumors, and the lowest expression was found in the normal pancreas. SEMA5A expression was localized on tumor cells with no staining in the surrounding stroma. To understand the functional significance of SEMA5A, we treated PC cell lines with recombinant SEMA5A. We observed an increase in migration, chemotaxis, and scattering of PC cells. To delineate the signaling axis of SEMA5A, we generated SEMA5A receptor-Plexin-B3 knockdown in T3M-4 and CD18/HPAF PC cell lines and observed that the effect of SEMA5A treatment was absent in the Plexin-B3 knockdown counterparts of T3M-4 and CD18/HPAF cells. SEMA5A treatment leads to phosphorylation of cMET in Plexin-B3 dependent manner. Our data demonstrate that there is an increase in SEMA5A expression during PC progression and the elevation of this expression takes place at metastatic sites especially the liver in both exocrine and endocrine tumors. SEMA5A can elicit a migratory response in cells by activating cMET through the Plexin-B3 receptor. In conclusion, SEMA5A signaling represents a potential molecule for targeting metastasis in pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)5931-5943
Number of pages13
JournalOncotarget
Volume9
Issue number5
DOIs
StatePublished - Jan 1 2018

Fingerprint

Semaphorins
Pancreatic Neoplasms
Neoplasm Metastasis
Neoplasms
Cell Line
Liver
Chemotaxis

Keywords

  • Metastasis
  • Pancreatic cancer
  • Pancreatic neuroendocrine tumors
  • Plexin-B3
  • Semaphorin-5A

ASJC Scopus subject areas

  • Oncology

Cite this

Pathological and functional significance of Semaphorin-5A in pancreatic cancer progression and metastasis. / Saxena, Sugandha; Hayashi, Yuri; Wu, Lingyun; Awaji, Mohammad; Atri, Pranita; Varney, Michelle L.; Purohit, Abhilasha; Rachagani, Satyanarayana; Batra, Surinder Kumar; Singh, Rakesh K.

In: Oncotarget, Vol. 9, No. 5, 01.01.2018, p. 5931-5943.

Research output: Contribution to journalArticle

Saxena, Sugandha ; Hayashi, Yuri ; Wu, Lingyun ; Awaji, Mohammad ; Atri, Pranita ; Varney, Michelle L. ; Purohit, Abhilasha ; Rachagani, Satyanarayana ; Batra, Surinder Kumar ; Singh, Rakesh K. / Pathological and functional significance of Semaphorin-5A in pancreatic cancer progression and metastasis. In: Oncotarget. 2018 ; Vol. 9, No. 5. pp. 5931-5943.
@article{13e519951fa84a3ab1b997e075132727,
title = "Pathological and functional significance of Semaphorin-5A in pancreatic cancer progression and metastasis",
abstract = "Semaphorin-5A (SEMA5A) has differential cell surface expression between normal and cancer cells and represents an attractive target for therapeutic intervention in pancreatic cancer (PC). In this study, we delineated the pathological expression and significance of SEMA5A during PC progression and metastasis. We utilized human tissue microarrays and different PC mouse models (Pdx1-cre; LSL- Kras(G12D), Pdx1- Cre; LSL-Kras(G12D); LSL-p53(R172H) and RIP1-Tag2) to analyze SEMA5A expression during PC progression. Using human patients and different mouse models, we demonstrated that SEMA5A expression was highest in liver metastases, followed by primary pancreatic tumors, and the lowest expression was found in the normal pancreas. SEMA5A expression was localized on tumor cells with no staining in the surrounding stroma. To understand the functional significance of SEMA5A, we treated PC cell lines with recombinant SEMA5A. We observed an increase in migration, chemotaxis, and scattering of PC cells. To delineate the signaling axis of SEMA5A, we generated SEMA5A receptor-Plexin-B3 knockdown in T3M-4 and CD18/HPAF PC cell lines and observed that the effect of SEMA5A treatment was absent in the Plexin-B3 knockdown counterparts of T3M-4 and CD18/HPAF cells. SEMA5A treatment leads to phosphorylation of cMET in Plexin-B3 dependent manner. Our data demonstrate that there is an increase in SEMA5A expression during PC progression and the elevation of this expression takes place at metastatic sites especially the liver in both exocrine and endocrine tumors. SEMA5A can elicit a migratory response in cells by activating cMET through the Plexin-B3 receptor. In conclusion, SEMA5A signaling represents a potential molecule for targeting metastasis in pancreatic cancer.",
keywords = "Metastasis, Pancreatic cancer, Pancreatic neuroendocrine tumors, Plexin-B3, Semaphorin-5A",
author = "Sugandha Saxena and Yuri Hayashi and Lingyun Wu and Mohammad Awaji and Pranita Atri and Varney, {Michelle L.} and Abhilasha Purohit and Satyanarayana Rachagani and Batra, {Surinder Kumar} and Singh, {Rakesh K}",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.23644",
language = "English (US)",
volume = "9",
pages = "5931--5943",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "5",

}

TY - JOUR

T1 - Pathological and functional significance of Semaphorin-5A in pancreatic cancer progression and metastasis

AU - Saxena, Sugandha

AU - Hayashi, Yuri

AU - Wu, Lingyun

AU - Awaji, Mohammad

AU - Atri, Pranita

AU - Varney, Michelle L.

AU - Purohit, Abhilasha

AU - Rachagani, Satyanarayana

AU - Batra, Surinder Kumar

AU - Singh, Rakesh K

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Semaphorin-5A (SEMA5A) has differential cell surface expression between normal and cancer cells and represents an attractive target for therapeutic intervention in pancreatic cancer (PC). In this study, we delineated the pathological expression and significance of SEMA5A during PC progression and metastasis. We utilized human tissue microarrays and different PC mouse models (Pdx1-cre; LSL- Kras(G12D), Pdx1- Cre; LSL-Kras(G12D); LSL-p53(R172H) and RIP1-Tag2) to analyze SEMA5A expression during PC progression. Using human patients and different mouse models, we demonstrated that SEMA5A expression was highest in liver metastases, followed by primary pancreatic tumors, and the lowest expression was found in the normal pancreas. SEMA5A expression was localized on tumor cells with no staining in the surrounding stroma. To understand the functional significance of SEMA5A, we treated PC cell lines with recombinant SEMA5A. We observed an increase in migration, chemotaxis, and scattering of PC cells. To delineate the signaling axis of SEMA5A, we generated SEMA5A receptor-Plexin-B3 knockdown in T3M-4 and CD18/HPAF PC cell lines and observed that the effect of SEMA5A treatment was absent in the Plexin-B3 knockdown counterparts of T3M-4 and CD18/HPAF cells. SEMA5A treatment leads to phosphorylation of cMET in Plexin-B3 dependent manner. Our data demonstrate that there is an increase in SEMA5A expression during PC progression and the elevation of this expression takes place at metastatic sites especially the liver in both exocrine and endocrine tumors. SEMA5A can elicit a migratory response in cells by activating cMET through the Plexin-B3 receptor. In conclusion, SEMA5A signaling represents a potential molecule for targeting metastasis in pancreatic cancer.

AB - Semaphorin-5A (SEMA5A) has differential cell surface expression between normal and cancer cells and represents an attractive target for therapeutic intervention in pancreatic cancer (PC). In this study, we delineated the pathological expression and significance of SEMA5A during PC progression and metastasis. We utilized human tissue microarrays and different PC mouse models (Pdx1-cre; LSL- Kras(G12D), Pdx1- Cre; LSL-Kras(G12D); LSL-p53(R172H) and RIP1-Tag2) to analyze SEMA5A expression during PC progression. Using human patients and different mouse models, we demonstrated that SEMA5A expression was highest in liver metastases, followed by primary pancreatic tumors, and the lowest expression was found in the normal pancreas. SEMA5A expression was localized on tumor cells with no staining in the surrounding stroma. To understand the functional significance of SEMA5A, we treated PC cell lines with recombinant SEMA5A. We observed an increase in migration, chemotaxis, and scattering of PC cells. To delineate the signaling axis of SEMA5A, we generated SEMA5A receptor-Plexin-B3 knockdown in T3M-4 and CD18/HPAF PC cell lines and observed that the effect of SEMA5A treatment was absent in the Plexin-B3 knockdown counterparts of T3M-4 and CD18/HPAF cells. SEMA5A treatment leads to phosphorylation of cMET in Plexin-B3 dependent manner. Our data demonstrate that there is an increase in SEMA5A expression during PC progression and the elevation of this expression takes place at metastatic sites especially the liver in both exocrine and endocrine tumors. SEMA5A can elicit a migratory response in cells by activating cMET through the Plexin-B3 receptor. In conclusion, SEMA5A signaling represents a potential molecule for targeting metastasis in pancreatic cancer.

KW - Metastasis

KW - Pancreatic cancer

KW - Pancreatic neuroendocrine tumors

KW - Plexin-B3

KW - Semaphorin-5A

UR - http://www.scopus.com/inward/record.url?scp=85040682092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040682092&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.23644

DO - 10.18632/oncotarget.23644

M3 - Article

C2 - 29464045

AN - SCOPUS:85040682092

VL - 9

SP - 5931

EP - 5943

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 5

ER -